-
The loss of roughly half the nations flu vaccine supply for the 2004-2005 season has infection control professionals scrambling to revamp their programs and secure adequate doses for health care workers and high-risk patients.
-
A novel influenza vaccine plagued by so much controversy the manufacturer almost gave up making it now is considered a good option for many health care workers during this seasons vaccine shortage, public health officials advise.
-
-
-
MediGene AG has initiated a clinical Phase I/II trial of the drug candidate NV1020 for the treatment of liver metastases developing from colorectal cancer.
-
Part 1 of 2: Indications, Mechanism of Action, Pharmacokinetics, Dosing & Administration, Adverse Events, amd Interactions. Cinacalcet is the first in a class of calcimimetic agents that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium.
-
Hydromorphone hydrochloride (Palladone); New indication for duloxetine hydrochloride (Cymbalta).
-
Rofecoxib, celecoxib (Celebrex), and valdecoxib (Bextra) are a subclass of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively block the enzyme COX-2 (cyclooxygenase-2). When Merck announced the rofecoxib withdrawal, it said that its study results were not necessarily applicable to others in the COX-2 inhibitor class.
-
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
-
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.
